Promising advancements in CAR T-cell therapy for large B-cell lymphoma (LBCL) include potential new safety parameters, opportunities for precision care, and increased chances of achieving remission ...
Allogene Therapeutics has announced an expanded collaboration with Foresight Diagnostics to develop a minimal residual disease (MRD) assay as a companion diagnostic tool for identifying patients with ...
Everyday Health on MSN
Who should be on your large B-cell lymphoma care team?
Having a well-rounded care team can make large B-cell lymphoma treatment easier. Learn how nurses, social workers, and other ...
In the EPCORE DLBCL-3 study, fixed-duration epcoritamab monotherapy delivered deep, durable responses with manageable ...
Everyday Health on MSN
How supportive care fits into large B-cell lymphoma treatment
Explore the benefits of supportive care in large B-cell lymphoma treatment. Learn how it can ease symptoms, boost quality of life, and more.
Patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) who received treatment with both CAR-T cell therapy and bendamustine chemotherapy prior to apheresis, or blood collection, ...
Lyell Immunopharma (LYEL) has made significant progress with respect to its CD19/CD20 CAR-T cell therapy targeting patients with aggressive 3rd-line + Large B-Cell Lymphoma [LBCL]. The reason why is ...
Allogene Therapeutics reports promising results for cema-cel, an allogeneic CAR T therapy for relapsed/refractory large B-cell lymphoma. Allogene Therapeutics has published promising results from its ...
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB): JNDA submission supported by results of Japanese and global phase 2 clinical trials evaluating epcoritamab in patients with mature ...
Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse Large B-Cell Lymphoma ...
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T ...
Patient Screening is Underway at Rocky Mountain Cancer Centers, Part of the US Oncology Network and Sarah Cannon Research Institute; Astera Cancer Care, Part of the OneOncology Network; and Norton ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback